Method for preventing and treating thrombogenesis

A technology of thrombosis and thromboembolism, which is applied in the field of medicine, can solve problems such as no thromboembolic disease, unknown dosage and method of medication, and no indication for thromboembolic disease

Inactive Publication Date: 2013-04-03
FUKANGREN BIO PHARMA
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Ozagrel hydrochloride has the same active ingredient as ozagrel sodium, but the dosage form marketed with ozagrel hydrochloride as the active ingredient is a tablet, which is mainly used for the prevention and treatment of bronchial asthma, and has no indication for the treatment of thrombotic diseases , and there is no relevant research on its use in the treatment of thromboembolic diseases. Compared with the injection of ozagrel sodium, whether oral preparations of ozagrel hydrochloride can be used for clinical antithrombotic treatment, the dosage and method of administration are still unknown

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method for preventing and treating thrombogenesis
  • Method for preventing and treating thrombogenesis
  • Method for preventing and treating thrombogenesis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0009] Make 1000 ozagrel tablets with the raw materials in the following weight ratio.

[0010]

[0011]

[0012] Preparation Process:

[0013] 1. The ozagrel raw material is crushed through an 80-mesh sieve and set aside.

[0014] 2. Pass the lactose through a 60-mesh sieve and set aside.

[0015] 3. Take ozagrel, pregelatinized starch, lactose, and cross-linked sodium carboxymethylcellulose and mix well.

[0016] 4. Make soft material with 5% PVPK30 solution, granulate with 20 mesh sieve, dry at 60°C, and granulate with 24 mesh sieve.

[0017] 5. Add external croscarmellose sodium and magnesium stearate, mix well, and press into tablets to get ready.

Embodiment 2

[0019] 1. Prepare 6% ethanol solution of Opadry enteric coating agent;

[0020] 2. Take the plain tablet obtained in Example 1, pour it into the coating pan, start the coating pan, and blow hot air, preheat the plain tablet at 30-40°C for 10 minutes, and blow off the drug powder adhering to the tablet core, Spray the coating solution evenly, so that the drug solution is evenly coated on the tablet core, and then the ozagrel enteric-coated tablet is obtained.

Embodiment 3

[0022] Make 1000 ozagrel tablets with the raw materials in the following weight ratio.

[0023]

[0024] Preparation:

[0025] 1. Grind Pirfenib and raw materials through an 80-mesh sieve, and set aside.

[0026] 2. Pass the lactose through a 60-mesh sieve and set aside.

[0027] 3. Take ozagrel and mix well with pregelatinized starch, lactose and microcrystalline cellulose.

[0028] 4. Make soft material with water, granulate with 20 mesh, dry at 60°C, and granulate with 24 mesh.

[0029] 5. Add croscarmellose sodium and magnesium stearate, mix well, and press into tablets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a method for preventing and treating thrombogenesis. The method comprises the step of supplying Ozagrel hydrochloride oral preparation to an object needing prevention and treating of thrombogenesis, with 25-800mg and 1-4 times each day.

Description

technical field [0001] The invention relates to a method for preventing and treating thrombosis, which belongs to the technical field of medicine. Background technique [0002] Ozagrel sodium is a highly effective and selective inhibitor of thromboxane synthase, which improves the imbalance between the two by inhibiting the production of thromboxane A2 (TXA2) and promoting the production of prostacyclin (PGI2), and has antiplatelet Aggregation and vasodilator action. It can inhibit cerebral vasospasm, increase cerebral blood flow, improve microcirculation disorder and abnormal energy metabolism in the brain, thereby improving cerebral ischemic symptoms in patients with subarachnoid hemorrhage and ataxia in patients with cerebral thrombosis (acute stage). The commonly used preparation is ozagrel sodium injection, 20mg each. Intravenous infusion after diluting with normal saline or glucose injection, 80mg per day. [0003] Ozagrel hydrochloride has the same active ingredien...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/4174A61P7/02A61P9/10A61P11/00
Inventor 不公告发明人
Owner FUKANGREN BIO PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap